|drug3589||WEB embolization Wiki||1.00|
There is one clinical trial.
Selection of the appropriate size of the device is mandatory during aneurysm treatment with a WEB. The Investigators aimed to investigate if virtual simulation with Sim&Size software may have an impact on technical, angiographic, and clinical outcomes after WEB treatment. Data from two large-volume centers were collected and compared (January 2017-January 2020). Virtual simulation was systematically adopted in one center, while conventional sizing was used in the other one. Outcomes were the duration of intervention, the radiation dose (mGy), the number of corrective interventions for inappropriate WEB size, the number of WEBs not deployed, angiographic occlusion, and complications. Univariate and multivariate linear models were adopted.
Description: the median duration of the interventionMeasure: Median duration of the intervention Time: 1day
Description: the median radiation doseMeasure: Median radiation dose Time: 1 day
Description: the need of corrective interventionsMeasure: Need of corrective interventions Time: 1 day
Description: the number of WEBs opened but finally not deployed because of the inappropriate size of the device.Measure: number of WEBs opened Time: 1 day
Description: the overall rate of complications (peri-procedural and long-term adverse events)Measure: Overall rate of complications Time: 1 day
Description: the morbidity rate (complications associated with permanent change of the clinical and neurological status of the patient)Measure: morbidity rate Time: 1 day
Description: short-term (6 months) and long-term (12 months or more) aneurysm occlusionMeasure: Rate of Aneurysm occlusion Time: 6 months and 12 months
Description: WEB-shape change ("compaction") (decrease in height of the device or a deepening of the proximal and distal concave recesses during follow-up9 based on non-subtracted images).Measure: WEB-shape change Time: 6 months and 12 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports